Devil facial tumor disease is a cancer that spreads from one Tasmanian devil to another through living tumor cells, not through a virus or bacterium. When an infected devil bites another on the face during fights or mating, clumps of cancer cells physically transfer into the wound and begin growing in the new host’s body as if they were that animal’s own tissue. The disease has driven one of the steepest wildlife declines in modern history, reducing the total devil population to roughly 17,000 by 2020, and it has become one of the most studied examples of a biological phenomenon once considered almost impossible: a cancer that behaves like an infectious disease.
A Cancer Made of Someone Else’s Cells
Most cancers begin when a cell in your own body mutates and grows out of control. DFTD works differently. The tumors that appear on a sick devil’s face are not made of that devil’s own cells. They are clones of cells from a single individual devil that lived decades ago. Every tumor on every infected devil traces back to that one original animal’s tissue, passed mouth to mouth across thousands of hosts over the years.
Genetic and gene-expression studies confirmed that the cancer cells originated from Schwann cells, a type of cell that normally wraps around nerve fibers and helps them conduct signals.1PubMed Central. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer The tumor cells still express proteins characteristic of myelinating Schwann cells, including a protein called periaxin that researchers use as a diagnostic marker to identify the disease.2PubMed. Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils: immunohistochemistry studies Because the cancer cells are alive and genetically distinct from the host, DFTD is not an infection in the traditional sense. It is more like an unwanted organ transplant that the devil’s body fails to reject.
Two Independent Cancer Lineages
Researchers initially assumed there was one transmissible cancer circulating in devil populations. Then, in 2014 and 2015, devils in southern Tasmania began turning up with facial tumors that looked the same on the outside but were histologically distinct under a microscope. Genetic testing showed these tumors were an entirely separate cancer, carrying a Y chromosome and having no cytogenetic similarity to the original lineage. The original cancer was renamed DFT1 and the new one DFT2.3PubMed Central. A second transmissible cancer in Tasmanian devils
Genomic analysis of 78 DFT1 and 41 DFT2 tumor samples suggests DFT1 first emerged around 1986 and DFT2 around 2011.4PubMed Central. The evolution of two transmissible cancers in Tasmanian devils Both originated from Schwann cells, but they arose independently from different individual devils.5PubMed Central. Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii) The fact that two separate transmissible cancers evolved in the same species suggests something about devil biology makes this kind of event less freakishly rare than scientists once assumed.
How the Tumor Dodges the Immune System
When your body receives a transplanted organ from another person, the immune system recognizes the foreign tissue and attacks it. The same should happen when devil tumor cells enter a new host. So why doesn’t it?
The answer lies in a molecular disguise. Healthy cells display identity markers on their surface, molecules known as MHC class I. These markers are what immune cells use to tell “self” from “non-self.” DFTD cells have shut down production of these identity markers, making them essentially invisible to the host devil’s immune system.6PubMed Central. How the devil facial tumor disease escapes host immune responses Without those surface markers, the devil’s immune cells cannot recognize the tumor as foreign tissue and mount a defense against it.
The shutdown is not caused by permanent genetic damage. It is an epigenetic change, meaning the genes for making MHC molecules are still intact but have been silenced. When researchers treated DFTD cells in the lab with interferon-gamma, the MHC molecules reappeared on the cell surface.7PubMed Central. Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer This reversibility became a central clue for vaccine research: if you could force the tumor cells to show their identity markers, the devil’s immune system might finally see and destroy them.
Why Devils Were Vulnerable in the First Place
Low genetic diversity at MHC genes is widely cited as a reason devils are so susceptible. But this vulnerability is not a recent development. Analysis of DNA from historical museum specimens and ancient samples dating back thousands of years shows that Tasmanian devils had limited MHC diversity long before Europeans arrived in Australia.8PubMed Central. Low major histocompatibility complex diversity in the Tasmanian devil predates European settlement and may explain susceptibility to disease epidemics This means the genetic bottleneck was not created by colonial-era habitat destruction or persecution. It was already a feature of the species, probably shaped by earlier population crashes.
With such similar MHC genes across the population, a foreign cell arriving via a bite wound looks less foreign than it would in a more genetically diverse species. The tumor cells barely register as “other.” Add the active MHC shutdown the tumor employs, and the immune system has almost nothing to work with. The combination of population-wide genetic uniformity and the tumor’s own stealth tactics is what makes DFTD so devastatingly efficient.
The Scale of Population Collapse
DFTD was first noticed in 1996 in northeastern Tasmania. By 2020, the disease had spread across more than 90% of the species’ range, causing local population drops averaging about 80% and reducing the total estimated population to around 16,900 animals.9PubMed Central. Quantifying 25 years of disease-caused declines in Tasmanian devil populations: host density drives spatial pathogen spread Separate monitoring over a longer time frame found an average decline of 77% at affected sites, with disease prevalence remaining stubbornly high despite the thinned-out populations.10PubMed Central. Density trends and demographic signals uncover the long-term impact of transmissible cancer in Tasmanian devils
The demographic profile of affected populations shifted dramatically. Sites with long-standing disease became dominated by young animals, because most adults did not survive long enough to grow old. DFTD typically kills within six to twelve months of visible tumor appearance. Tumors grow rapidly around the face and mouth, eventually interfering with the animal’s ability to eat. Starvation and secondary infections are the usual causes of death.
What Happens When You Lose an Apex Predator
Tasmanian devils are the largest surviving marsupial carnivore, and their decline has sent ripples through the island’s ecosystems. In areas where devil numbers crashed earliest, researchers found increased activity of feral cats and black rats, alongside reduced numbers of small and medium native prey species. The pattern suggested that devils had been playing a keystone role, and without them, invasive predators expanded to fill the gap.11PubMed. Disease-induced decline of an apex predator drives invasive dominated states and threatens biodiversity Follow-up work using remote cameras and experimental carcass placement confirmed that mesopredators consumed more carrion in low-devil areas, and feral cats in particular seemed to respond to a relaxed “landscape of fear” where devils were suppressed.12PubMed Central. Top carnivore decline has cascading effects on scavengers and carrion persistence
The picture is not entirely straightforward, though. At least one statewide camera survey found no clear negative relationship between devil and feral cat abundance, and no statistically significant trophic cascades from devil decline to cat abundance to quoll abundance across the disease timeline.13PLOS ONE. Devil Declines and Catastrophic Cascades: Is Mesopredator Release of Feral Cats Inhibiting Recovery of the Eastern Quoll? The discrepancy likely reflects differences in spatial scale, survey timing, and local habitat structure. In broad terms, evidence points to real ecological consequences from the devil’s decline, but the cascade from lost predator to lost biodiversity does not play out identically everywhere on the island.
Signs of Natural Resistance
Despite the grim population numbers, something unexpected started showing up in long-diseased populations: some devils were fighting back. Genomic comparisons of devil populations sampled before and after DFTD arrived revealed strong selection at two chromosomal regions containing genes linked to cancer risk and immune function in other mammals. These changes appeared independently in three separate devil populations, suggesting rapid natural selection in as few as four to six generations.14Nature Communications. Rapid evolutionary response to a transmissible cancer in Tasmanian devils
Even more striking, a handful of wild devils developed antibodies against DFT1 cells and experienced spontaneous tumor regression. In one study, four of six devils that had mounted an antibody response saw their tumors disappear entirely when retrapped months later.15PubMed Central. Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils These cases are still rare, but they demonstrated that the devil immune system is not fundamentally incapable of recognizing and destroying DFTD. It just needs the right trigger.
Vaccine and Drug Research
The discovery that MHC molecules could be switched back on in tumor cells pointed researchers toward vaccine strategies. In immunotherapy trials, devils were injected with DFTD cells that had been treated to re-express MHC class I on their surface. Three devils that received this treatment showed tumor regression, and the shrinkage correlated with antibody responses against DFTD cells.16Scientific Reports. Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils Subsequent immunization trials refined the approach, using MHC-expressing DFTD cells as the basis for vaccination protocols and producing antibody responses in a majority of devils destined for wild release.17PubMed Central. Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release
On the pharmaceutical side, several drug candidates have shown promise in the lab. Large-scale screening identified DFTD tumor cells as highly vulnerable to tyrosine kinase inhibitors targeting ERBB receptors, with drugs like lapatinib and erlotinib killing tumor cells effectively. Separate experiments showed that STAT3 inhibitors could also kill DFTD cells specifically.18Cancer Cell. The Origins and Functional Analysis of Tasmanian Devil Facial Tumor Disease Meanwhile, atorvastatin, a cholesterol-lowering statin widely used in human medicine, shut down the energy metabolism of DFTD cells and prevented tumor growth in a mouse xenograft model, offering what the researchers called a feasible biochemical treatment option.19PubMed. LXR stimulates a metabolic switch and reveals cholesterol homeostasis as a statin target in Tasmanian devil facial tumor disease The immunomodulatory drug imiquimod also induced cell death in both DFT1 and DFT2 lines, though at high concentrations and with continuous treatment required to maintain the effect.20PLOS ONE. The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines
Translating any of these from the lab into a treatment you can administer to wild marsupials that bite when handled is, of course, a different challenge. No drug has yet been deployed as a standard field treatment. But having multiple candidates across different mechanisms gives conservation biologists options to work with.
Detecting the Disease Earlier
By the time a tumor is visible on a devil’s face, the disease is already well established. Earlier detection would allow managers to isolate or treat infected animals before they spread cells to others. Researchers identified ERBB3, a protein produced at elevated levels in the blood of infected devils, as a potential biomarker. Devils with DFT1 showed significantly higher serum ERBB3 levels than unaffected animals, raising the possibility of a blood test that could flag disease before tumors become visible.21PLOS ONE. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)
Field surveillance is also getting faster. A point-of-care diagnostic test has been developed that can detect DFT1 from non-invasive swab samples in the field, eliminating the need to send biopsies to a distant laboratory.22CrossRef. Development of a point-of-care field diagnostic test for DFT1 and DFT2 For a species that lives in remote bushland and is mostly active at night, these kinds of rapid-turnaround tools make a real practical difference in how quickly management decisions can be made.
Insurance Populations and Genetic Safeguards
While researchers worked on treatments and vaccines, conservation managers pursued a parallel strategy: keep a disease-free population alive somewhere safe. A captive insurance program was established in 2006, and a wild population was introduced onto Maria Island, a small island off Tasmania’s east coast where DFTD had not arrived.23Conservation Genetics. Pedigree reconstruction using molecular data reveals an early warning sign of gene diversity loss in an island population of Tasmanian devils (Sarcophilus harrisii) Genetic analysis has shown that both the captive metapopulation and the Maria Island group are representative of range-wide genetic diversity, including diversity at the specific loci associated with DFTD resistance, even though these populations have not been exposed to the selective pressure of the disease.24PubMed Central. Restoring faith in conservation action: Maintaining wild genetic diversity through the Tasmanian devil insurance program
Managing genetic diversity in small captive populations is tricky. Early signs of gene diversity loss were detected on Maria Island through pedigree reconstruction, a warning that even well-intentioned conservation introductions can lose variation quickly if not managed carefully. The broader insurance program has responded by carefully tracking pedigrees and moving animals between facilities to maintain as much genetic breadth as possible. The goal is not just to keep devils alive, but to keep them genetically equipped to survive if returned to the wild.
A more speculative proposal has explored whether devils could be reintroduced to mainland Australia, where they went extinct roughly 3,000 years ago. Habitat modeling suggests climatically suitable forest areas exist in southeastern Australia, and ecological modeling predicts that devils could assume a predator role similar to dingoes in places where dingoes have been removed, suppressing feral cats and overabundant wallabies.25Biological Conservation. Reintroduction of Tasmanian devils to mainland Australia can restore top-down control in ecosystems where dingoes have been extirpated Whether this ever happens depends on a long list of ecological and political hurdles, but the modeling at least raises it as something beyond fantasy.
Transmissible Cancers Are Not Unique to Devils
DFTD would be remarkable enough on its own, but it is part of a small and growing club. The best-known parallel is canine transmissible venereal tumor, or CTVT, a sexually transmitted cancer that has been circulating among dogs worldwide for thousands of years.26Oncogene. Clonally transmissible cancers in dogs and Tasmanian devils Unlike DFTD, CTVT is ancient and relatively benign; it often regresses on its own after several months. The contrast is illuminating. CTVT has had millennia to co-evolve with its hosts, reaching a kind of détente in which the cancer persists without killing. DFTD is young and has no such equilibrium.27Trends in Genetics. Insights from Transmissible Tumors
More recently, researchers discovered that transmissible cancers are widespread in marine bivalves. Disseminated neoplasias, essentially leukemia-like cancers of the blood, have been identified as clonally transmissible in cockles, mussels, and clams. In soft-shell clams, one cancer lineage even crossed over from a closely related species.28Nature. Widespread transmission of independent cancer lineages within multiple bivalve species At least ten bivalve species are now known to harbor some form of transmissible neoplasia.29PLOS Pathogens. Variation in natural infection outcomes and cancer cell release from soft-shell clams (Mya arenaria) with bivalve transmissible neoplasia Together with the two independent DFTD lineages in devils and CTVT in dogs, these findings have reshaped how biologists think about cancer. Transmissible cancers are no longer a biological curiosity confined to one or two freak cases. They appear to arise more often than anyone guessed, especially in species with certain biological vulnerabilities like low genetic diversity or frequent physical contact that enables cell transfer.
For human medicine, the practical risk is essentially zero. Our immune systems are genetically diverse enough and our physical interactions rarely involve the kind of open-wound cell transfer that devil biting creates. But the basic science of how DFTD evades immunity, how it evolves as it spreads, and how hosts can be coaxed into recognizing it has generated insights that connect to broader questions about cancer immunology, transplant rejection, and evolutionary biology. A marsupial cancer on an Australian island has become, improbably, one of the more instructive model systems in modern oncology.